Diamyd Medical
10.48 SEK -2.42%1 investor is following this company
Diamyd Medical is a diabetes company. The company develops the diabetes vaccine Diamyd® with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd® to global Phase III trial.
Revenue
550K
EBIT %
-19,080 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
DMYD B
Daily low / high price
10.3 / 10.58
SEK
Market cap
1.09B SEK
Turnover
727.71K SEK
Volume
70K
Latest videos
Financial calendar
Interim report
2024-06-26
Annual report
2024-10-09
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Avanza Pension | 12.9 % | 10.2 % |
Bertil Lindkvist | 9.1 % | 7.2 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Diamyd Medical AB: Diamyd Medical publishes prospectus with regards to the rights issue
Diamyd Medical AB: Quarterly Report II 23/24
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools